Successful treatment of triple-negative breast cancers (TNBC) (estrogen receptor (ER)-negative, progesterone receptor-negative and Her-2-negative), that are also p53 mutant remains elusive. This evidence concerns the gene TP53 and triple-negative breast carcinoma.